This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): R1550, huHMFG1, Therex
Description: AS1402 is a humanised version of the mouse monoclonal antibody HMFG1. It binds to MUC1, a cell membrane protein present in a variety of tumours of epithelial origin, including breast, ovarian, pancreatic, gastric, and colon cancers. Published data suggest that AS1402 acts as a 'marker flag', attaching itself to tumour cells and helping components of the immune system, including natural killer cells, to find and destroy them. Humanisation is intended to make the antibody less immunogenic (i.e. to make the antibody less likely to be recognised as foreign material by the patient's immune system) and thus increase its suitability for repeat intravenous administration.
Deal Structure: AS1402 was formerly being developed by Roche under the Antisoma-Roche alliance. In June 2006, Antisoma reached agreement with Roche to regain all rights to AS1402.
In March 2011, Biothera announced that it has acquired AS1402 from Antisoma for undisclosed terms.
Additional information available to subscribers only: